Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!
FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.
/ 7 items
#AMRX↓
Amneal Acquires Kashiv BioSciences in $1.1B Deal to Ride $300 Billion Biosimilar Wave
Amneal is buying Kashiv BioSciences for up to $1.1 billion to become a global leader in affordable biosimilar drugs. Strong Q1 results beat expectations and 2026 guidance raised.
UBS Sees 6-9% Growth for Amneal: Why the Recent Dip is a Buying Opportunity
UBS starts coverage on Amneal Pharmaceuticals with a Buy rating. Strong specialty growth, Parkinson’s drugs, and attractive entry point after recent selloff.
FDA Approves Amneal's Denosumab Biosimilars for Bone Health
Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment.
FDA Approves Amneal’s New Epinephrine Injection Vials for Emergency Care
The FDA has approved Amneal Pharmaceuticals’ new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings.
Amneal's Generic Bimatoprost Ophthalmic Solution Approved by FDA
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.